Similar articles

• ORTHO EVRA and venous thromboembolism: an update.

  Jick SS, Hagberg KW, Kaye JA. Jick SS, et al. Contraception. 2010 May;81(5):452-3. doi: 10.1016/j.contraception.2009.12.016. Epub 2010 Jan 27. Contraception. 2010. PMID: 20399954 No abstract available.
• Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.

  Jick S, Kaye JA, Li L, Jick H. Jick S, et al. Contraception. 2007 Jul;76(1):4-7. doi: 10.1016/j.contraception.2007.03.003. Epub 2007 May 11. Contraception. 2007. PMID: 17586129
• Transdermal hormonal contraception: benefits and risks.

  Burkman RT. Burkman RT. Am J Obstet Gynecol. 2007 Aug;197(2):134.e1-6. doi: 10.1016/j.ajog.2007.04.027. Am J Obstet Gynecol. 2007. PMID: 17689623
• Advances in hormonal contraception.

  Gupta N. Gupta N. Adolesc Med Clin. 2006 Oct;17(3):653-71; abstract xi. doi: 10.1016/j.admecli.2006.06.015. Adolesc Med Clin. 2006. PMID: 17030284 Review.
• A review of post-marketing safety and surveillance data for oral contraceptives containing norgestimate and ethinyl estradiol.

  Lippman JS, Shangold GA. Lippman JS, et al. Int J Fertil Womens Med. 1997 Jul-Aug;42(4):230-9. Int J Fertil Womens Med. 1997. PMID: 9309456 Review. No abstract available.